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Hypertension, which affects one in three 
adults in the United States,1 is a leading 
risk factor for heart disease, stroke, and 
diabetes—the first, fifth, and seventh 
leading causes of death in this country, 
respectively.2 High blood pressure costs 
an estimated $48.6 billion each year, 
including $3.6 billion in lost productivity 
and $45.0 billion in direct medical 
expenses.3 Controlling blood pressure 
and other risk factors can substantially 
lower cardiovascular disease mortality 
and morbidity, but only 54% of people 
with high blood pressure have their 
condition well controlled.1 
The Community Preventive Services 
Task Force, an independent panel 
of public health and prevention 
experts, recommends team-based 
care approaches to improve blood 
pressure control. The recommendation 
is based on strong evidence that these 
approaches are effective. The Task Force 
found that when health care teams 
included pharmacists, their hypertensive 
patients were significantly more likely 
to have controlled blood pressure than 
were hypertension patients overall. 
Moreover, when team members were 
allowed to modify antihypertensive 
drug therapy, either independently 
or with the primary care provider’s 
authorization, medication adherence 
was greater.5 Pharmacists can improve 
the management of chronic conditions 
like hypertension and diabetes by 
providing drug therapy management, 
counseling, education, and other health 
care services.6,7 In addition, studies and 
systematic reviews have demonstrated 
reduced health care use when 
pharmacists are included on the health 
care team and found the team-based 
care approach to be cost effective.5,8
To become pharmacists, students 
must obtain a doctor of pharmacy 
degree (Pharm.D.) and pass a national 
standardized licensing exam. In 
addition, pharmacists can receive 
advanced training and certification, 
including clinical residencies in various 
specialty areas, such as chronic disease 
management. This level of training, 
combined with state laws authorizing 
pharmacists to enter into collaborative 
practice agreements (CPAs) with 
physicians and other prescribers, allows 
pharmacists to provide collaborative 
drug therapy management (CDTM) 
and other advanced coordinated patient 
care services. As of 2012, 46 states had 
authorized pharmacists to engage in 
CPAs or CDTM through legislation or 
administrative regulations, although the 
range of services authorized varied  
by state.4
This report describes the experience of 
Osterhaus Pharmacy, an independent 
community pharmacy in eastern Iowa 
that formed collaborative relationships 
with two local medical groups of family 
practice physicians, physician assistants, 
and nurse practitioners: Medical 
Associates of Maquoketa and Maquoketa 
Family Clinic. Osterhaus participated in 
the Collaborative Practice Agreement 
Case Study Project, which was launched 
in September 2011 to better understand 
how state laws authorizing CPAs are 
being put into action. The case study 
project, which included the Osterhaus 
Pharmacy case study, focused on 
community settings where pharmacists 
collaborated with physicians and nurse 
practitioners to provide services that 
improved chronic disease management 
and related health outcomes for patients. 
Its findings are intended to inform and 
guide practitioners and others who are 
considering adopting CPA policies or 
implementing CDTM. 
Collaborative drug therapy management
is a collaborative practice agreement between one or more health 
professionals and pharmacists in which qualified pharmacists working 
within the context of a defined protocol are permitted to assume 
professional responsibility for performing patient assessments; ordering 
drug therapy–related laboratory tests; administering drugs; and selecting, 
initiating, monitoring, continuing, and adjusting drug regimens.9
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Setting
Overview of Iowa  
CPA Legislation
Iowa regulates the practice of CDTM by 
physicians and pharmacists through  
rules promulgated by the Iowa Board  
of Medicine and the Iowa Board of  
Pharmacy (Table 1). The regulations set 
forth distinct requirements for CDTM in  
a hospital versus a community setting 
that include written protocols, pharmacist 
qualifications, and record-keeping 
procedures. In a community pharmacy 
setting, the parties must enter into  
a community practice protocol (CPP), 
through which the physician delegates 
specific CDTM duties to a pharmacist. 
A CPP is a written, signed agreement to 
engage in CDTM between an authorized 
pharmacist and a physician establishing 
drug therapy management criteria  
“for one or more of the pharmacist’s  
and physician’s patients residing in  
a community setting” (e.g., a home, 
group home, assisted living facility, 
correctional facility, hospice, long-term 
care facility).
The supervising physician has the 
ultimate responsibility for patient care.
Osterhaus Pharmacy
Osterhaus Pharmacy is a family-owned, 
independent community pharmacy 
practice established in 1965 in 
Maquoketa, Iowa. The pharmacy also 
serves as a pharmacy residency training 
program practice site, hosting  
1 resident and 12 to 15 students each 
year. Approximately 6,500 patients visit 
the pharmacy annually, and about 
60% have diabetes, hypertension, or 
hyperlipidemia. Osterhaus offers a variety 
of patient care services and emphasizes 
caring for the aging population. The 
seven pharmacists on staff strive to 
provide high-quality, personalized, and 
cost-effective services in an environment 
“where you know your pharmacist and 
your pharmacist knows you.”12
Collaborative practice is embedded 
into the culture at Osterhaus Pharmacy; 
staff described collaboration as “the way 
we do things here.” Osterhaus and the 
two local medical practices (Medical 
Associates of Maquoketa and Maquoketa 
Family Clinic) have a shared history of 
collaboration: They have engaged in 
CDTM for more than 5 years, and they 
engaged in non-CDTM collaborations 
before Iowa adopted CDTM regulations 
in 2006. In addition, the pharmacy and 
Medical Associates of Maquoketa jointly 
relocated to the same building several 
years ago to provide patients with more 
convenient access to services. 
Table 1. Regulations Relevant for this Case Study
Relevant Regulations
Iowa Board of Medicine
• Iowa Admin. Code r. 653 § 13.4(148) (2012): Supervision of pharmacists engaged in 
collaborative drug therapy management.
• Iowa Admin. Code r. 653 § 13.3(147) (2012): Supervision of pharmacists who administer  
adult immunizations.10
Iowa Board of Pharmacy • Iowa Admin. Code r. 657 § 8.34(155A) (2012): Collaborative drug therapy management.11
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Osterhaus Pharmacy Patient  
Population Stats
• 13% enrolled in Medicaid
• 42% enrolled in Medicare12
Maquoketa, Iowa  
Population Stats
• 96% white
• 17% below poverty level13
Implementation
CDTM Implemented at 
Osterhaus Pharmacy
Osterhaus Pharmacy put its initial CDTM 
program into action through a CPA with 
Medical Associates of Maquoketa and 
Maquoketa Family Clinic: a medication 
substitution protocol. 
The medication substitution 
protocol—begun in 1995—does not 
include any significant changes to dose 
or therapeutic effect, but it does allow 
pharmacists to substitute medications 
based on availability, patient preference, 
or insurance for five reasons:
1. To enhance adherence or  
patient acceptance.
2. To substitute extended-release 
medications with the same 
chemical entity.
3. To dispense the preferred product  
of the patient’s insurance carrier.
4. To convert nystatin topical cream  
to miconazole topical cream,  
or convert Medrol Dosepak  
to prednisone.
5. To clarify shorthand orders  
for insurance company  
audit issues.
Osterhaus implemented a second 
CPA, an immunization protocol, 
with Maquoketa Family Clinic. The 
immunization protocol, implemented 
in 2005, originally authorized Osterhaus’ 
pharmacists to administer injectable 
influenza vaccine in compliance with 
Chapter 155.A, section 155A.3, of 
the Iowa Pharmacy Practice Act. The 
pharmacy and clinic later expanded 
the protocol to include all adult 
immunizations and pediatric influenza 
vaccinations for people aged 6 years  
or older.
Osterhaus Pharmacy, Medical Associates 
of Maquoketa, and Maquoketa Family 
Clinic established CPAs to improve 
patient care. The pharmacists reported 
that the CPAs worked well and helped to 
maintain the working relationship with 
the collaborating physicians.
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Additional CPAs Implemented at Osterhaus Pharmacy After 2012
When the Collaborative Practice Agreement Case Study Project was completed in 2012, Osterhaus’ pharmacists planned 
to continue to expand their working relationship with both clinics and to establish more comprehensive CPAs with the 
medical groups in the future. The pharmacy and the two medical clinics have continued to expand their collaboration 
since the completion of the report for the case study project. 
• In 2013, Osterhaus Pharmacy established a CPA with both Medical Associates of Maquoketa and Maquoketa Family 
Clinic to enhance the availability of epinephrine auto injectors (EpiPens) for patients with allergy conditions who 
might need emergency treatment. The CPA allows the pharmacists to assess the patient’s need for an EpiPen due 
to an expired pen or prescription. The pharmacists may also use a questionnaire to determine whether a patient 
previously without an EpiPen prescription meets the criteria for an EpiPen.
• In 2014, Osterhaus established an informal collaborative arrangement with two prescribers at Medical Associates 
of Maquoketa to monitor patients with hypertension. Pharmacists check blood pressure and pulse and monitor 
adherence and response to therapy. They then share results and recommendations with the prescribers via fax. 
To date, Osterhaus has identified seven patients not at goal, and prescribers respond to and accept most of their 
recommendations within 24 hours. Also in 2014, the pharmacy added monitoring for diabetic patients, including 
blood glucose meter downloads shared with the prescriber in a user-friendly format, to enhance diabetes control.
• In 2015, Osterhaus established a CPA with Maquoketa Family Clinic to offer pharmacogenomics lab testing to their 
patients. Pharmacy staff do a cheek swab, which is submitted to the lab, and the pharmacy evaluates the results 
and makes recommendations to the prescriber. Osterhaus Pharmacy is initially targeting patients on clopidogrel, 
antidepressants, and antipsychotic medications.
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Facilitators of CDTM Implementation
The pharmacists and physicians 
have an established working 
relationship. Osterhaus Pharmacy 
and Medical Associates of Maquoketa 
have experience working together to 
provide non-CDTM services. The existing 
professional relationships between 
pharmacists and physicians, along with 
open and regular communication and a 
shared vision for collaboration, provided 
the foundation for a smooth transition to 
providing CDTM services. As pharmacists 
successfully worked with physicians 
to provide patient care, physician and 
pharmacist buy-in increased and the 
professional relationships already in 
place were strengthened.
The CPAs provide an additional 
avenue for pharmacist-physician 
collaboration. The two CPAs 
implemented at Osterhaus provide 
additional opportunities for pharmacists 
and physicians to collaborate. Osterhaus 
pharmacists and the prescribers from 
Medical Associates of Maquoketa and 
Maquoketa Family Clinic who have 
engaged in CDTM through the two 
CPAs are well-positioned to establish 
additional and more comprehensive 
CPAs in the future.
The pharmacy serves as a training  
site for residents and students, 
who are often interested in CDTM. 
The resident and pharmacy students 
in training at Osterhaus each year have 
interests and expertise that the pharmacy 
could use to conduct CDTM-related 
projects. Interviewees—including a 
pharmacist, a physician, and a pharmacy  
resident—believed that these 
students and recent graduates are 
more likely to be open to and skilled 
at pharmacist-physician collaboration, 
perhaps because of a shift in schools of 
pharmacy, medicine, and nursing to a 
more collaborative training approach 
and increased training opportunities in 
collaborative patient care.
Barriers to CDTM Implementation
Lack of reimbursement for 
pharmacists. Osterhaus pharmacists 
reported that, because pharmacists are 
not recognized as health care providers 
under the Social Security Act and cannot 
bill for services, they receive limited 
compensation for providing CDTM 
services. The Osterhaus pharmacists 
were compensated for providing 
vaccines under the immunization 
protocol. Additionally, because of 
the time and resources required to 
implement CDTM for the relatively small 
population of CDTM-eligible patients 
(compared with the total pharmacy 
patient population), CDTM may not be 
cost-effective, although Osterhaus did 
not perform a formal cost-effectiveness 
analysis. As a result, Osterhaus had no 
financial incentive to enter into a more 
extensive level of CDTM.
Pharmacists’ limited access to 
patient clinical information. The 
pharmacy and medical practice did not 
have a shared electronic health record 
system. As a result, the pharmacists 
sometimes lacked access to current 
and complete patient health records, 
hindering their ability to make 
recommendations for patients.
Walk-in patient visits to physicians. 
Medical Associates of Maquoketa and 
Maquoketa Family Clinic often accept 
patients on a walk-in basis, which 
could make it difficult for pharmacists 
to coordinate their provision of CDTM 
services with patients’ physician visits.
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Logistical and administrative 
challenges. Being a small, independent 
community pharmacy, Osterhaus 
lacked the time and administrative 
resources (e.g., staffing capacity, data 
collection system) necessary to develop, 
operationalize, and evaluate additional 
or more comprehensive CPAs.
The specificity of CDTM regulations. 
Interviewees expressed concern 
that the specificity of the state’s 
CDTM regulations could act as an 
administrative or logistical barrier 
in the future if the pharmacy opts 
to implement additional or more 
comprehensive CPAs (e.g., addressing 
additional disease states or medications).
Lessons Learned
Build CDTM into existing 
collaborative practice. Osterhaus 
pharmacists set the groundwork for 
successful CPA implementation by 
building relationships with Medical 
Associates of Maquoketa and 
Maquoketa Family Clinic prescribers 
that did not require a CPA. For example, 
the pharmacy and medical practice 
collaborate to provide medication 
therapy management services to 
patients through the Iowa Medicaid 
Pharmaceutical Case Management 
(PCM) program. The PCM program 
was implemented in 2000 and enables 
pharmacists and physicians to work 
together to serve Medicaid enrollees 
who take four or more medications for 
chronic conditions.
Allow enough time to lay the 
groundwork for successful 
collaboration. Pharmacists noted that 
it can take time to lay the groundwork 
for the level of collaboration necessary 
to successfully implement CDTM. They 
reported a strong sense of satisfaction 
from working collaboratively with 
physicians, and interviewees said 
that the collaboration strengthened 
the existing professional relationship 
between pharmacists and physicians.
Make CDTM a win-win-win for all 
stakeholders. Osterhaus Pharmacy, 
Medical Associates of Maquoketa, and 
Maquoketa Family Clinic developed 
their CPAs with an aim of making the 
collaborations successful for patients, 
physicians, and pharmacists, which 
helped ease the implementation 
process. Pharmacists may need to 
continually highlight the benefits of 
collaboration to physicians and patients 
in the short term to successfully 
carry out CDTM over the long term. 
Osterhaus staff also reported that having 
champions from key stakeholder  
groups can help facilitate successful 
CDTM implementation.
Emphasize a team-based  
approach to patient care.  
Successful implementation of CDTM 
requires a strong sense of teamwork, 
trust, and communication between 
providers. To optimize patient health 
outcomes, pharmacists and physicians 
should work as a team to solve problems 
and address patient needs.
Maintaining high physician 
participation in CPAs is important to 
expand pharmacists’ roles on health 
care teams in the long term. In 2012, 
approximately 80% of the prescribers 
for the two clinics were engaged in 
the CPAs. CDTM may require some 
physicians to shift away from a traditional 
model of care to a more collaborative 
approach that involves working 
alongside other health care providers 
such as pharmacists. To continue to 
expand the role of pharmacists on health 
care teams in the long term, Osterhaus 
and the two clinics will need to maintain 
physician buy-in and participation  
in CDTM.
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Summary and Conclusions
The Osterhaus Pharmacy case 
study provided useful insight into 
implementing a model of CDTM 
involving an independent community 
pharmacy and local independent 
medical clinics. The two CPAs were 
carried out as planned despite a few 
ongoing challenges, including lack 
of reimbursement for pharmacists 
providing CDTM, limited access 
for pharmacists to patient clinical 
information, and logistical challenges. 
However, pharmacy leaders leveraged 
the available resources—in particular, 
their existing collaborative relationships 
with physicians—to facilitate successful 
implementation. Although Osterhaus did 
not have the capacity to conduct formal 
evaluations of patient health outcomes, 
the pharmacists reported that the CPAs 
worked as intended.
Successful CDTM implementation 
requires a strong sense of teamwork 
between providers and high physician 
buy-in and participation. Osterhaus 
was successful in creating this sense 
of teamwork and can continue to 
grow its role in health care teams 
by expanding physician buy-in and 
participation in CDTM initiatives and 
developing additional CPAs. To develop 
additional and more comprehensive 
CPAs, Osterhaus Pharmacy will need to 
overcome logistical and administrative 
challenges (e.g., staffing capacity, data  
collection system).
Osterhaus Pharmacy has many assets 
that it could leverage to develop 
additional or more comprehensive  
CPAs in the future. These include  
a strong collaborative relationship with 
physicians, successful existing CPAs, 
and pharmacy students and residents 
on rotation at the pharmacy who have 
expertise and interest in CDTM. With 
these key elements already in place, 
pharmacists at Osterhaus are well 
positioned to play an even greater role 
on health care teams to improve patient 
health outcomes.
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